Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 59.3141
- Book/Share 20.4356
- PB 35.5644
- Debt/Equity 1.8705
- CurrentRatio 1.2777
- ROIC 0.2757
- MktCap 685007718320.0
- FreeCF/Share 2.0198
- PFCF 377.7061
- PE 47.0919
- Debt/Assets 0.3387
- DivYield 0.008
- ROE 0.8836
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Published: February 20, 2025 by: CNBC
Sentiment: Positive
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the company's Chief Scientific Officer Dan Skovronsky.
Read More
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Published: February 20, 2025 by: CNBC
Sentiment: Positive
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.
Read More
3 Stocks That Could Trounce the Market in 2025
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Read More
Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs
Published: February 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
LLY Rises More Than 4% in a Week: How to Play the Stock
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Read More
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Published: February 13, 2025 by: MarketBeat
Sentiment: Positive
Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.
Read More
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000